Diagnostic Criteria and Active Therapy Options through Medicine in Patients with Multiple Myeloma

Authors

  • Andika Ridwan Nugraha Harahap University of Lampung
  • Risal Wintoko
  • Rasmi Zakiah Oktarlina

DOI:

https://doi.org/10.53089/medula.v12i1.417

Keywords:

diagnostic, drug therapy, multiple myeloma

Abstract

Multiple myeloma (MM) is a malignant proliferation of plasma cells and plasmacytoid cells in the bone marrow, which is almost always characterized by the presence of monoclonal immunoglobulin (Ig) or Ig fragments in serum or urine. Multiple myeloma is the second most common haematological malignancy in high-income countries. However, the incidence is increasing worldwide. The number of yearly cases is estimated to nearly double in 20 years. All patients suspected of having a diagnosis of multiple myeloma should undergo an important examination because the disease is generally asymptomatic. Therefore, it is necessary to know the diagnostic criteria for MM to be able to manage it appropriately. When a patient is first diagnosed with myeloma, it is important to accurately classify and stage their disease so that it is hoped that the patient’s quality of life can be improved. Improved quality of life is seen with better treatments, including medication by drugs. The goal of treatment is to reduce the disease burden to such a low level that further damage cannot occur. In recent decades, corticosteroids, alkylating agents and anthracyclines (standard chemotherapy), proteasome inhibitors, immunomodulators, histone deacetylase inhibitors, and monoclonal antibodies, have become FDA-approved drug-based therapies of choice. Different drug combinations can be compared to first-line active treatment with one drug if possible.

Author Biographies

Andika Ridwan Nugraha Harahap, University of Lampung

 

 

Risal Wintoko

 

 

Rasmi Zakiah Oktarlina

 

 

References

Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA. 2022;327(5):464–477. doi:10.1001/jama.2022.0003

Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–61.

Alexanian R , Dimopoulos M . The treatment of multiple myeloma. N Engl J Med. 1994;330:484–9

Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015 May 30;385(9983):2197-208.

Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018; 378: 241- 249

Jewell S, Xiang Z, Kunthur A, Mehta P. Multiple Myeloma: Updates on Diagnosis and Management. Fed Pract. 2015;32(Suppl 7):49S-56S

Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management [published correction appears in Am J Hematol. 2020 Nov;95(11):1444]. Am J Hematol. 2020;95(5):548-567. doi:10.1002/ajh.25791

Chawla SS, Kumar SK, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015; 95: 57- 64.

Hillengass J, Moulopoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017; 7:e599.

Kumar S, Rajkumar SV. The multiple myelomas — current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018; 15: 409- 421

Rajkumar VS, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101–119.

National Institute for Health and Care Excellence. Myeloma: diagnosis and management (NICE guidelines [NG35]), 2016, https://www.nice.org.uk/guidance/ng35

Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 2019; 98: 19–28

Neal AJ, Hoskin PJ. Clinical oncology. 4th ed. London: CRC Press, 2012.

Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliat Care Soc Pract. 2019;13:1178224219868235. doi:10.1177/1178224219868235

Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 2016; 9: 51

Wang Y, Sanchez L, Siegel DS, et al. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol 2016; 9: 55

Published

2022-07-30

How to Cite

Harahap, A. R. N., Wintoko, R., & Oktarlina, R. Z. (2022). Diagnostic Criteria and Active Therapy Options through Medicine in Patients with Multiple Myeloma. Medical Profession Journal of Lampung, 12(1), 100-106. https://doi.org/10.53089/medula.v12i1.417

Issue

Section

Artikel

Most read articles by the same author(s)

1 2 > >>